3. RICH LEGACY, PROMISING FUTURE
1st brick in the
foundation laid
by late Mr. J.B.
Mody by
incorporating J.
B. Mody
Chemicals and
Pharmaceutical
s Limited.
1985 1986
2000
2003
2007
2008
2016
2020
2021
Forayed into the
cardiac segment
with the
revolutionary
product
Nicardia.
Iconic
product
Rantac
introduced
Received first
FDA approval for
our Panoli Plant:
T10.
Made a strategic
investment in a
company in
South Africa
called Biotech
Laboratories..
Leading private equity
firm Kohlberg Kravis
Roberts & Co. Inc. (KKR),
acquired a controlling
stake of JBCPL.
Introduced brands in
Russia, that went on
to become leading
OTC products in the
cough and cold
segment.
Got publicly listed
and expanded from
API to Formulation Launched the
product Cilacar
that went on to
become a leading
brand in
cardiology and
nephrology
Received a silver award
from the United States
Pharmacopeia (USP)
for participation in the
Monograph
Development &
Upgradation Program,
and preparation and
distribution of USP
reference substance
Ranked 25th in the Industry
(IQVIA) with 5 brands: Rantac
Metrogyl, Nicardia and Cilacar-T
featuring in top 300 brands of
the Indian pharmaceutical
market.
New therapeutic categories
introduced: Diabetes,
Nephrology, Respiratory,
Virology.
1976
1977
Introduced
the product
Metrogyl,
that went
on to
become the
‘gold
standard’ in
the
industry
10. What % of
hypertensive patients present with signs and symptoms of organ
damage, within the early years of being hypertensive?
1. 5-15%
2. 15-25%
3. 25-35%
4. 35-45%
5. More than 45%
11. Early Onset Hypertension Is Associated with
Hypertensive End-Organ Damage Already by Mid-Life
Hypertension. 2019 August ; 74(2): 305–312.
Our findings suggest that
hypertensive TOD is
robustly associated with
early onset hypertension
already by mid-life
12. The prevalence of microalbuminuria (MA) among
hypertensives and its relation to the
duration of hypertension – Indian study 150 patients
Kottayam Medical College, Kerala, South India,
between May 2005 and October 2006
Saudi J Kidney Dis Transpl 2008;19(3):411-419
13. Do you agree that consistently uncontrolled BP > 150mmHg can lead to
and hasten end-organ damage?
1. Yes
2. No
3. May be
14. In hypertensive patients, how frequently should physicians ask for a
microalbuminuria / UACR testing done?
1. Every 3 months
2. Every 6 months
3. Once every year
15. What are the outcomes from anti-hypertensive therapy, that are
crucial for a physician in his patients of diabetic hypertension?
1. Molecule’s efficacy in reducing BP numbers
2. Molecule’s capability for end organ protection
3. Both the above outcomes are equally crucial
16. What are the advantages of selecting Cilnidipine + Telmisartan
combination therapy in diabetic hypertensive patients?
1. Combination therapy helps in greater BP numbers reduction
2. Synergism between molecules is beneficial in reno-protection
3. Different modes of action ensure sustained anti-hypertensive action
17. Trials for Reno-Protection with Cilnidipine
CARTER
TRIAL
J-Circle
Study
CLEARED
Study
Results suggest that
switching from amlodipine
to cilnidipine results in a
significant reduction in
urinary ACR as well as
significant reduction in uric
acid production. Thus,
cilnidipine is more useful
than amlodipine in
improving albuminuria and
uric acid metabolism in
hypertensive patients with
chronic kidney disease
Cilnidipine had greater anti-
proteinuric effects than
amlodipine in hypertensive
patients who had kidney
disease associated with
significant proteinuria
Combination therapy with
cilnidipine and an ARB
ameliorated urinary albumin
excretion more potently than
ARB monotherapy.
N = 339 N = 70 N = 90
Switching of the treatment from
the L-type CCB to cilnidipine
resulted in significant reduction of
the UAE, whereas switching from
cilnidipine to the L-type CCB
resulted in no significant change
in the UAE. This study
demonstrated that the
antialbuminuric effect of
Cilnidipine, but not the L-type
CCBs, was sustained even in
patients treated for a long time.
Diabetes Res Clin Pract . 2012 Jul;97(1):91-8.; ||| J Clin Hypertens (Greenwich) . 2014 Oct;16(10):746-53. doi: 10.1111/jch.12412. ||| Kidney Int. 2007 Dec;72(12):1543-9. doi: 10.1038/sj.ki.5002623.
18. In hypertensive patients with SBP > 150mmHg, beginning right away
with combination therapy (like Cilnidipine + Telmisartan) is the
preferred choice
1. Strongly agree
2. Agree
3. Neutral
4. Disagree
5. Strongly Disagree
19. 19
Restores the
podocin and nephrin
expression, protects
the podocytes
Afferent and
Efferent arterioles
(L&N channel
blocking), thus
reduced glomerular
pressure
Inhibits oxidative
stress, Ameliorates
urinary albumin
excretion and
decreases urinary 8-
OHdG and L-FABP
Inhibits the renal
RAS system
Cilnidipine has multiple approaches in reno-protection
J Hypertens. 2010 May; 28(5): 1034–1043.
Hypertens Res. 2012 Nov;35(11):1058-62. doi: 10.1038/hr.2012.96.
20. Do you find Cilnidipine (10mg) + Telmisartan (40mg) + combination to
be clinically relevant in difficult-to-manage hypertension?
1. Strongly agree
2. Agree
3. Neutral
4. Disagree
5. Strongly disagree
21. Which of the below clinical benefits have you most frequently seen
with Cilnidipine + Telmisartan combination therapy in your diabetic
hypertensive patients?
1. Reno-protection, reduction in UACR
2. Consistent, reliable and Smooth BP reduction
3. No reflex tachycardia, visibly normalized sympathetic overdrive
4. Minimal pedal edema, well tolerated
5. All of the above
22. What percentage of young Indian
hypertensive patients (Age less than 50 years) that present with
microalbuminuria in your practice?
1. 10-20%
2. 20-30%
3. 30-40%
4. 40-50%
5. More than 50%
23. Do you believe that sympathetic over activity in hypertensive patients,
enhances the progression of kidney damage?
1. Strongly agree
2. Agree
3. Neutral
4. Disagree
5. Strongly disagree
24. ARB + Cilnidipine as an add-on CCB, is one the preferred therapies to
manage sympathetic overactivity in hypertensive patients, thus
improving the overall renal outcomes?
1. Strongly agree
2. Agree
3. Neutral
4. Disagree
5. Strongly disagree
